Baxter Nov. 26 announced new allocation levels for multiple IV product groups and advised customers of a one- to two-week ...

IV Choline Chloride has the potential to become the ... Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of ...